ClinicalTrials.gg
RecruitingNCT07561567E20241186Updated May 1, 2026

Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device

An observational study in Lung Cancer, Non-Small Cell, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital — 24 open to participants now, 25 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Tianjin Medical University Cancer Institute and Hospital.

Started
2026
with 6 others
Observational
2 of 50
1 open now
Primary completion
2026-12
later than 13 of 24 live
Registered
48th of 50
by date

Among the 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital, this one is one of 7 that started in 2026, is one of 2 observational ones, reaches primary completion later than 13 of the 24 other live ones, and was the 48th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

24 of the 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital are open now, in 1 country. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 24 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to understand the safety and effectiveness of abdominal pressure devices in inhibiting respiratory movement in lung cancer patients. The main question it aims to answer is:

Did the abdominal pressure device reduce the respiratory movement of participants with lung cancer tumors?

Participants will:

Record how much they use abdominal pressure devices to suppress lung cancer tumor respiratory movement

03

Conditions studied

  • Lung Cancer, Non-Small Cell

Keywords

  • Respiratory Movement Management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This trial will enroll 50 patients with NSCLC scheduled to receive SBRT

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinical diagnosis is solitary peripheral lung cancer, and after comprehensive evaluation by the participating physicians based on the patient's clinical data, it is suitable for receiving SBRT treatment;

Exclusion criteria

Exclusion Criteria:

Central or super central lung cancer patients who are intolerant or unwilling to undergo respiratory suppression and chest and abdominal compression fixation

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Breathing management group

    CT/4DCT scan under breathing management

    Device: Chest and abdominal compression · Device: breathing management

  • No breathing management group

    CT/4DCT scan under free breathing

Interventions

  • DeviceChest and abdominal compression

    Abdominal compression suppresses respiratory movement in patients

  • Devicebreathing management

    Apply pressure to the patient's abdomen to achieve respiratory movement inhibition

06

What researchers measure

Primary outcomes

  1. Tumor displacement range

    Based on 4DCT for delineating tumor motion range and extracting radiomics features in patients with and without respiratory management

    Time frame: Within 6 months after enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 7 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 1, 2026
StartEst.
May 10, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07561567
Responsible party
Sponsor
First posted
May 1, 2026
Start date
May 10, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 1, 2026

Study contacts

Xuyao Yu Dr
Contact
yuxuyao@tmu.edu.cn
86-022-23341405

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion